{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:09:39Z","timestamp":1789711779900,"version":"4.0.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer-associated dermatomyositis (CADM) is a rare paraneoplastic syndrome characterized by inflammatory myopathy and distinctive cutaneous manifestations. Early recognition of an underlying malignancy is essential for improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 48-year-old woman who initially presented with dermatomyositis as the first manifestation of breast cancer. She was admitted with progressive dysphagia, violaceous edematous erythema involving the face and neck, and proximal muscle weakness of the extremities. The patient had previously been diagnosed with idiopathic dermatomyositis at another institution and treated with glucocorticoids; however, her symptoms showed no significant improvement. Further evaluation at our hospital revealed markedly elevated muscle enzyme levels. Autoantibody testing demonstrated weak positivity for anti-Jo-1 antibodies and positivity for anti-Ro-52 antibodies. Both skin and muscle biopsies supported the diagnosis of dermatomyositis. Comprehensive malignancy screening subsequently identified invasive carcinoma of the right breast with axillary lymph node metastasis. Following treatment with glucocorticoids combined with two cycles of neoadjuvant chemotherapy consisting of paclitaxel and platinum-based agents, the patient\u2019s skin lesions markedly regressed, muscle strength improved, and dysphagia was significantly alleviated. She subsequently underwent radical breast surgery followed by adjuvant radiotherapy, and her condition has remained stable during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      A review of the literature indicates that age &amp;gt;40 years, dysphagia, rapid disease progression, and positivity for anti-transcription intermediary factor 1-gamma a\n                      <jats:italic>nti<\/jats:italic>\n                      -\n                      <jats:italic>TIF<\/jats:italic>\n                      1-\n                      <jats:italic>\u03b3<\/jats:italic>\n                      antibodies are important risk factors for CADM. Thorough malignancy screening should be performed in all newly diagnosed patients with dermatomyositis, particularly for common associated malignancies such as breast cancer, lung cancer, ovarian cancer, and nasopharyngeal carcinoma. Clinicians should maintain a high index of suspicion for occult malignancy in patients who respond poorly to conventional dermatomyositis therapy. Early identification and effective treatment of the underlying malignancy are critical for improving the prognosis of CADM.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1907254","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:39:03Z","timestamp":1789709943000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: breast cancer presenting as dermatomyositis"],"prefix":"10.3389","volume":"16","author":[{"given":"Qinchuan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Oncology, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12356956","article-title":"Dermatomyositis and Malignancy","volume":"100","author":"Bernard","year":"1993","journal-title":"J Invest Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01648.x","article-title":"Polymyositis and dermatomyositis associated with Malignancy: a 30-year retrospective study","volume":"41","author":"Wakata","year":"2002","journal-title":"Int J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.014","article-title":"Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes","volume":"29","author":"Selva-O'Callaghan","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci156025","article-title":"Using autoantibody signatures to define cancer risk in dermatomyositis","volume":"132","author":"Turnier","year":"2022","journal-title":"J Clin Invest"},{"key":"B11","first-page":"89","article-title":"Paraneoplastic dermatomyositis","volume":"65","author":"Moses","year":"2017","journal-title":"J Assoc Physicians India"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/ogx.0b013e3181efb12a","article-title":"Paraneoplastic dermatoses associated with gynecologic and breast Malignancies","volume":"65","author":"Levine","year":"2010","journal-title":"Obstet Gynecol Surv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad396","article-title":"Janus kinase inhibitor for anti-transcription intermediary factor 1-\u03b3 positive cancer-associated dermatomyositis","volume":"190","author":"Wu","year":"2024","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","article-title":"Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review","volume":"51","author":"Muro","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3761","article-title":"The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants","volume":"30","author":"Didona","year":"2020","journal-title":"Eur J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/s0190-9622(98)70263-4","article-title":"Dermatomyositis","volume":"39","author":"Kovacs","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00281-025-01054-9","article-title":"Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment","volume":"47","author":"Ali","year":"2025","journal-title":"Semin Immunopathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000043758","article-title":"Robot-assisted surgery for rectal cancer with tumor-associated dermatomyositis during preoperative chemotherapy: a case report and literature review","volume":"104","author":"Sawamura","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28030182","article-title":"A case of pathological complete response and resolution of dermatomyositis following neoadjuvant chemotherapy in HER2-positive early breast cancer","volume":"28","author":"Piras","year":"2021","journal-title":"Curr Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1503140","article-title":"Risk, risk factors, and screening of Malignancies in dermatomyositis: current status and future perspectives","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416665601","article-title":"Risk of Malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40257-015-0120-1","article-title":"Cancer risk in dermatomyositis: a meta-analysis of cohort studies","volume":"16","author":"Olazagasti","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"B23","article-title":"Incidence and predictive factors for Malignancies with dermatomyositis: a cohort from southern China","volume":"32","author":"Chen","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13075-025-03662-0","article-title":"Revisiting the link between oropharyngeal dysphagia and cancer in autoimmune myositis: a descriptive study","volume":"27","author":"Shen","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094128","article-title":"Factors predicting Malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis","volume":"9","author":"Lu","year":"2014","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08922-4","article-title":"Autoantibody markers of increased risk of Malignancy in patients with dermatomyositis","volume":"63","author":"Marz\u0119cka","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2026.100460","article-title":"Autoantibodies as biomarkers of cancer risk in dermatomyositis","volume":"6","author":"Bax","year":"2026","journal-title":"JID Innov"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170544","article-title":"Increased levels of soluble programmed death ligand 1 associate with Malignancy in patients with dermatomyositis","volume":"45","author":"Chen","year":"2018","journal-title":"J Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01111-x","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152619","article-title":"Established and novel insights to guide cancer assessment in patients with idiopathic inflammatory myopathies","volume":"71","author":"Ceribelli","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae629","article-title":"Prognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicentre cohort study of 73 patients","volume":"64","author":"Teboul","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0569-22","article-title":"A case in which breast cancer developed at the same time as dermatomyositis, and the onset of new cancer was able to be predicted by the exacerbating skin symptoms and parallel increase in the anti-TIF1-\u03b3 antibody levels","volume":"62","author":"Akagi","year":"2023","journal-title":"Intern Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3892\/ol.2025.15055","article-title":"Rare diagnosis of locally advanced triple-negative breast cancer with paraneoplastic dermatomyositis: a case report and literature review","volume":"29","author":"Song","year":"2025","journal-title":"Oncol Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1474481","article-title":"Dermatomyositis following resection of thyroid and breast cancer: a case report and literature review","volume":"15","author":"Yang","year":"2025","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1907254\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:39:05Z","timestamp":1789709945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1907254\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1907254"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1907254","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1907254"}}